文献速递眼底病与葡萄膜炎

自主人工智能系统在内分泌门诊进行糖尿病视网膜病变筛查的真实世界整合

Real-world integration of an autonomous artificial intelligence system for diabetic retinopathy screening in an endocrinology outpatient clinic.
PubMed 文献 · Br J Ophthalmol · 2026-06-29

本研究评估自主AI系统AEYE-DS联合Topcon NW500相机在内分泌门诊进行糖尿病视网膜病变(DR)筛查的真实世界整合。256例无既往DR的糖尿病患者由非眼科新手操作者拍摄非散瞳黄斑中心眼底照片,95.7%获得明确结果,29.6%筛查阳性,其中44.7%完成确认性检查,11.8%接受治疗。患者满意度高,支持可扩展的即时自主筛查和阶梯转诊。

要点

  • 非散瞳下95.7%(245/256)获得明确AI筛查结果。
  • 11.8%(4例)需抗VEGF或全视网膜光凝治疗。

核心结论

  • 在内分泌门诊真实世界中,AEYE-DS联合Topcon NW500实现了高效DR筛查和高非散瞳成像率。
  • 捕获了临床相关比例需眼科评估的患者,内部转诊确认性检查便于评估下游结局。
  • 结果支持可扩展的即时自主筛查及对AI阳性患者采用阶梯转诊方式。

研究设计与样本

  • 单中心真实世界临床整合研究,纳入无既往DR的1型或2型糖尿病成人患者。
  • 由非眼科新手操作者拍摄非散瞳、黄斑中心眼底照片,AEYE-DS分析检测重于轻度DR(mtmDR)。
  • AI阳性者由医生咨询并自动转诊至机构内确认性检查。

主要发现

  • 95.7%(245/256)参与者无需药物散瞳即获得明确AEYE-DS结果。
  • 4例(占已评估者的11.8%)需玻璃体腔抗VEGF治疗或全视网膜光凝。
  • AI阳性患者中识别出若干既往未识别的其他眼部疾病。
  • 患者满意度高,>80%报告筛查易用、省时且值得推荐。

关键数值与推荐

  • 阳性定义为检测重于轻度DR(mtmDR)。
  • 明确结果率95.7%(245/256),无药物散瞳。
  • 需治疗比例11.8%(4例),患者满意度>80%。

临床怎么用

  • 可在内分泌门诊由非眼科人员使用自主AI进行非散瞳DR筛查。
  • AI阳性患者应自动转诊至眼科进行确认性检查。
  • 采用阶梯转诊方式可优化资源并评估下游治疗结局。

局限性

  • 外部完成的随访未被捕获,可能低估确认性检查完成率和治疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate a real-world clinical integration of an autonomous artificial intelligence (AI) system (AEYE Diagnostic Screening (AEYE-DS), AEYE Health, USA) for diabetic retinopathy (DR) screening using the Topcon NW500 camera (Topcon, Japan) in an endocrinology clinic. METHODS: Adults with type 1 or type 2 diabetes without previously reported DR attending routine endocrinology follow-up were invited to participate. Non-mydriatic, macula-centred fundus photographs were acquired by a novice, non-ophthalmic operator. Images were analysed by AEYE-DS to detect more-than-mild DR (mtmDR). AI-positive results prompted physician counselling and automated referral for internal confirmatory examination. RESULTS: Definitive AEYE-DS results were obtained for 95.7% (245/256) of participants without pharmacological dilation. Seventy-six (29.6%) patients screened positive for mtmDR, of whom 34 (44.7%) completed confirmatory examination at the institution's retina clinic; externally completed follow-up was not captured. Four patients (11.8% of those evaluated) required treatment with intravitreal anti-vascular endothelial growth factor therapy or panretinal photocoagulation. Additional previously unrecognised ocular conditions were identified among several AI-positive patients. Patient satisfaction was high, with >80% reporting the screening was easy to use, time-efficient and recommendable. CONCLUSIONS: In a real-world endocrinology clinic, autonomous AI screening for DR using AEYE-DS integrated with the Topcon NW500 enabled efficient DR screening and achieved high non-mydriatic imageability. A clinically relevant proportion of patients requiring ophthalmic evaluation has been captured. Internal referral for confirmatory testing enabled assessment of downstream outcomes. The findings support scalable, point-of-care autonomous screening and a stepped-referral approach for AI-positive patients.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gil O, Arad A, Fogel M, et al. Real-world integration of an autonomous artificial intelligence system for diabetic retinopathy screening in an endocrinology outpatient clinic. Br J Ophthalmol. 2026. PMID: 42373309. doi:10.1136/bjo-2025-328991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。